0 43 eps expected for intellia therapeutics inc ntla 4

$-0.43 EPS Expected for Intellia Therapeutics Inc. (NTLA)

March 1, 2018 – By marketbeat

Analysts expect Intellia Therapeutics Inc. (NASDAQ:NTLA) to report $-0.43 EPS on March, 13.They anticipate $0.12 EPS change or 38.71 % from last quarter’s $-0.31 EPS. After having $-0.44 EPS previously, Intellia Therapeutics Inc.’s analysts see -2.27 % EPS growth. The stock decreased 4.15% or $1.13 during the last trading session, reaching $26.1. About 1.02 million shares traded or 10.11% up from the average. Intellia Therapeutics Inc. (NASDAQ:NTLA) has declined 46.16% since March 1, 2017 and is downtrending. It has underperformed by 62.86% the S&P500.

Intellia Therapeutics Inc. (NASDAQ:NTLA) Ratings Coverage

Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Tuesday, May 31. Wedbush initiated Intellia Therapeutics Inc. (NASDAQ:NTLA) on Tuesday, May 31 with “Outperform” rating. Jefferies initiated it with “Hold” rating and $33 target in Tuesday, May 31 report. The firm has “Buy” rating given on Friday, August 5 by Jefferies. Leerink Swann upgraded the stock to “Outperform” rating in Friday, August 5 report.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $1.11 billion. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

More recent Intellia Therapeutics Inc. (NASDAQ:NTLA) news were published by: Globenewswire.com which released: “Intellia Therapeutics to Present at February Healthcare Investor Conferences” on January 31, 2018. Also Fool.com published the news titled: “Here’s What Pushed Intellia Therapeutics Inc. Up 33.7% in January” on February 08, 2018. Globenewswire.com‘s news article titled: “Intellia Therapeutics to Present at March Healthcare Investor Conferences” with publication date: February 28, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Back To Top